ccs

DC_AC50 is a dual inhibitor of Atox1 and CCS (copper chaperones), aimed at reducing or preventing acquired chemotherapy resistance by inhibiting intracellular copper chaperones. It binds to Atox1 and CCS, thereby reducing cancer cell proliferation and tumor growth.

Inobrodib (CBP-IN-1) is a potent inhibitor of p300/CBP bromodomain.

Oxaliplatin (L-OHP) is a DNA alkylating agent, an inhibitor of DNA synthesis. Oxaliplatin causes DNA cross-linking damage, preventing DNA replication and transcription and leading to cell death. Oxaliplatin induces autophagy.

Calmidazolium chloride (R 24571) is a calmodulin (CaMK) antagonist with a Kd of 3 nM, which inhibits CaM-dependent phosphodiesterase (IC50 = 0.15 μM) and calmodulin-induced activation of erythrocyte Ca2+-transporting ATPase (IC50 = 0.35 μM). It also induces apoptosis in certain cancer cell lines.

Sulfo-SMCC sodium, a widely utilized non-cleavable, hetero-bifunctional crosslinker for antibody-drug conjugates (ADCs), features both N-hydroxysuccinimide (NHS) ester and maleimide groups. These functionalities enable it to specifically react with primary amines and sulfhydryl groups, respectively.

CuATSM is a cell-permeable copper complex and PET tracer for selective hypoxia imaging. It also exhibits neuroprotective potential in ALS and Parkinson's disease by mitigating oxidative damage.

DA-PROTAC is a potent degrader of the copper ion-transport proteins Atox1 and CCS, capable of binding to both proteins and facilitating their association with E3 ligase. This interaction enhances the ubiquitination and subsequent proteasomal degradation of Atox1 and CCS. DA-PROTAC is utilized in triple negative breast cancer research [1].